We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Both glaucoma and cancer of the eye may lead to temporary or permanent vision loss, among other vision-related challenges. Early stages of open-angle glaucoma may not cause evident symptoms.

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Among patients with suspected or confirmed glaucoma, higher average blood pressure and greater variability in blood pressure ...

Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal ...

New study challenges conventional wisdom about cholesterol! High levels of 'good cholesterol' may increase the risk of ...

Patients with primary open-angle glaucoma or ocular hypertension who ... KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, I. Paul Singh, MD, explains excimer laser ...

Travatan Z (travoprost) is a prescription drug used to lower eye pressure in people with open-angle glaucoma or ocular hypertension. The drug comes as an eyedrop solution. It’s usually given ...

That’s why Optegra Eye Hospital Bradford is supporting ... estimated that around 2% of people over the age of 40 have open angle glaucoma, the most common form. The prevalence increases with ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).